Daxor Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Daxor şirketinin toplam hissedar öz sermayesi $32.7M ve toplam borcu $1.6M olup, bu da borç-öz sermaye oranını 5.1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $34.4M ve $1.7M dir.

Anahtar bilgiler

5.1%

Borç/özkaynak oranı

US$1.65m

Borç

Faiz karşılama oranı	n/a
Nakit	n/a
Eşitlik	US$32.66m
Toplam yükümlülükler	US$1.72m
Toplam varlıklar	US$34.38m

Son finansal sağlık güncellemeleri

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: DXR 'nin kısa vadeli varlıkları ( $20.1K ) kısa vadeli yükümlülüklerini ( $70.6K ) kapsamıyor.

Uzun Vadeli Yükümlülükler: DXR 'un kısa vadeli varlıkları ( $20.1K ) uzun vadeli yükümlülüklerini ( $1.6M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: DXR 'nin net borç/öz sermaye oranı ( 5.1% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: DXR 'nin borç/öz sermaye oranı son 5 yılda 32.3% seviyesinden 5.1% seviyesine düştü.

Borç Kapsamı: DXR 'nin işletme nakit akışı negatif olduğundan borçlar iyi karşılanamıyor.

Faiz Kapsamı: DXR şirketinin borçlarına ilişkin faiz ödemelerinin EBIT tarafından iyi bir şekilde karşılanıp karşılanmadığını belirlemek için yeterli veri yok.

Daxor Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Nasdaq Staff Determines Daxor Complies with Nasdaq’s Audit Committee Requirement Set in Listing Rule 5605

Recent updates

Daxor Corporation, Annual General Meeting, Jul 15, 2024

Nasdaq Staff Determines Daxor Complies with Nasdaq’s Audit Committee Requirement Set in Listing Rule 5605

Daxor Corporation Announces Two New Studies Validating the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

New minor risk - Profit margin trend

New minor risk - Financial data availability

Daxor Corporation Announces New Data from Duke University Medical Center Validating the Benefits of Blood Volume Analysis

Investor sentiment deteriorates as stock falls 16%

Daxor Corporation Submits Dual 510(K)/CLIA-Waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer

Investor sentiment improves as stock rises 20%

Daxor Corporation Announces the Presentation of Data from a Phase I National Institute of Health Sponsored Randomized Control Trial from Two Veterans Affairs Medical Centers

Daxor Corporation Announces New Data from Banner University Medicine Demonstrating Effectiveness of Bva-100 Use in Ambulatory Heart Failure Patients Presented At Heart Failure Annual Scientific Meeting

JACC-HF Reports Successful Heart Failure Trial with Daxor BVA-100®

Daxor Corporation Announces New Research Letter About Heart Failure Validating the Benefits of BVA-100 Diagnostic in Optimizing Individualized Therapy

Insufficient new directors

Daxor Corporation, Annual General Meeting, Jul 11, 2023

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $4.000035 million.

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $4.000035 million.

Investor sentiment deteriorates as stock falls 26%

Investor sentiment improves as stock rises 23%

Investor sentiment deteriorated over the past week

Daxor Corporation has completed a Follow-on Equity Offering in the amount of $2.000007 million.

Daxor Corporation Study Demonstrates Significant Clinical Utility of Daxor's Blood Volume (Bva-100(R)) Diagnostic in the Evaluation of Heart Failure

Investor sentiment deteriorated over the past week

Daxor Corporation Announces New Data Validating Benefits of BVA-100 Diagnostic Blood Test in Reducing Hospital Length of Stay (LOS) for Heart Failure (HF) Patients

Daxor Corporation to Report Q2, 2022 Results on Aug 25, 2022

Daxor reports Q2 results

Daxor partners with Medaxiom to advance awareness of blood volume diagnostic

Daxor Corporation, Annual General Meeting, Jun 23, 2022

Daxor's (NASDAQ:DXR) Earnings Aren't As Good As They Appear

Daxor Corporation Announces New Data Demonstrating the Importance and Clinical Utility of Daxor’s Bva-100 Blood Test in Heart Failure (Hf) Patients Published in the Journal of Cardiac Failure

Daxor Corporation Announces Patient Enrollment Completion and Updates Data Analysis

Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society Meeting

Daxor Corporation Provides Update on American College of Cardiology (ACC) Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure Patients

Daxor Corporation Announces the Initiation of A Multi-Center Clinical Trial with Two Veterans Affairs Medical Centers to Evaluate Blood Volume Analysis Guided Management of Acute Decompensated Heart Failure Utilizing the BVA-100 Blood Test

Daxor Corporation Announces Newly Published Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)

Daxor Corporation Announces Novel Fluorescent Tracer and Phase-Two US Air Force Contract Award of $750,000 for Point-Of-Care Optical Blood Volume Analyzer

Revenue and earnings miss expectations

A Look At The Fair Value Of Daxor Corporation (NYSEMKT:DXR)

New 90-day low: US$11.49

Daxor Corporation Announces New Data from the University of Hawaii John A. Burns School of Medicine Showing the BVA-100 Blood Test

Daxor Corporation Announces New Distribution Agreement with L1 Enterprises Government Distributor

New 90-day low: US$12.10

New 90-day low: US$12.55

Wake Forest Baptist Health Joins Multicenter Covid-19 Bva-100 Blood Test Study

New 90-day low: US$13.85

New 90-day low: US$14.61

Daxor Corporation Announces Compelling New Data Demonstrating Further Beneficial Use of Blood Volume Analysis Technology Presented During the Heart Failure Society of America’s Virtual Annual Scientific Meeting 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin